Intraperitoneal and Appendiceal Malignancies
Abstract
Abstract
BACKGROUND: Patients with colorectal cancer (CRC) and peritoneal metastases (PM) have a poor prognosis. The efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) remains controversial. This study aimed to evaluate the efficacy of HIPEC combined with cytoreductive surgery (CRS) and systemic therapy in these patients. Methods PubMed, Web of Science, Embase, and the Cochrane Library were searched from their inception to March 2026. The primary outcomes were progression-free survival (PFS) and overall survival (OS). Treatment effects were quantified as pooled hazard ratios (HRs) with 95% confidence intervals (CIs). Results This meta-analysis included 12 studies (2 randomized controlled trials (RCTs), 9 cohort studies, and 1 case-control study), encompassing >2700 patients. Pooled analysis showed that the addition of HIPEC significantly improved OS (HR=0.60, 95%CI:(0.51, 0.70), P<0.001, I2=18.2%), with a 40% reduction in mortality, and significant PFS benefit (HR=0.51, 95%CI:(0.30, 0.87), P=0.013, I2=76.3%), with a 49% reduction in the risk of progression or death. Subgroup analyses demonstrated consistent OS benefits across regions (Eastern: HR=0.50, 95%CI:(0.32, 0.78); Western:HR=0.62, 95%CI:(0.52, 0.74)) and follow-up durations (<30 months: HR=0.57, 95%CI:(0.51, 0.63); ≥30 months: HR=0.60, 95%CI:(0.42, 0.85)). No significant OS benefit was observed in either the peritoneal cancer index (PCI)<11 (HR=0.71, P=0.089) or PCI≥11 (HR=0.53, P=0.063) subgroups. Regarding PFS, a significant benefit was observed only in patients with PCI<11 (HR=0.74, P=0.043), whereas no significant difference was found in those with PCI≥11 (HR=0.45, P=0.066). Conclusion HIPEC combined with CRS and systemic therapy significantly improves prognosis in patients with CRC and PM.
Direct answer
What can I do from this paper page?
Use this page to scan "Hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery and systemic therapy improves prognosis in colorectal cancer with peritoneal metastases: an updated meta-analysis." quickly: start with the summary and abstract, then check the authors, source, topics, and related papers. From here, open Scollr to follow Intraperitoneal and Appendiceal Malignancies research, save the paper, or map adjacent work.
Research areas
Follow related topics
Citation
BibTeX
@article{Hu2026Hyperthermic,
title = {Hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery and systemic therapy improves prognosis in colorectal cancer with peritoneal metastases: an updated meta-analysis.},
author = {K Q Hu and Xuanhao Hu and Ting Jiang and Xuelian Dai and Yixuan Wu and Zhongxuan Xie and Qili Yu},
journal = {PubMed},
year = {2026},
doi = {10.1159/ocl/aebag002},
url = {https://pubmed.ncbi.nlm.nih.gov/42636179}
}FAQ
Using this paper in a discovery workflow
How do I find related work for this paper?
Use the related papers and topic links on this page as starting points. In Scollr, you can also open the paper and build a literature map around its references, citing papers, and related work.
How can I keep up with new Intraperitoneal and Appendiceal Malignancies research papers?
Follow Intraperitoneal and Appendiceal Malignancies research in Scollr. New papers from the topic flow into a personalized feed, and you can save useful studies to revisit later.
Can I cite this paper from this page?
This page includes a static BibTeX block for Hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery and systemic therapy improves prognosis in colorectal cancer with peritoneal metastases: an updated meta-analysis.. Always verify the DOI, source, and publication details against the publisher record before submitting a manuscript.
Follow this research in Scollr
Follow the topics and authors behind this paper, save useful studies, and build a literature map when you are ready to go deeper.
Get the app